Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Phase I/II Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells VCAR33 in Patients with Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation
Study Type: Treatment
Phase: I/II
NCTID: NCT05984199
Principal Investigator:
Muhammad Umair Mushtaq
Phase I Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Dociparstat Sodium in Combination with Standard Chemotherapy for the Treatment of Newly-Diagnosed Acute Myeloid Leukemia
An Open-Label, Phase I, Multi-Center Study to Determine in Relapsed/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome or B-Cell Non-Hodgkin Lymphoma Patients the Recommended Dose of CYAD-02 After A Non-Myeloablative Preconditioning Chemotherapy Followed By A Potential CYAD-02 Consolidation Cycle for Non-Progressive Patients CYCLE-1 ? CYAD-02 NKG2D CAR-T Clinical dEvelopment
A phase 1/2 study of CPX-351 (NSC#775341) Alone followed by Fludarabine, Cytarabine and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML)
Study Type: Treatment
Phase: I/II
NCTID: NCT02642965
Principal Investigator:
Keith August
A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia, Intermediate or Higher-Risk Myelodysplastic Syndromes, bcr-abl negative Myeloproliferative, Myelodysplastic/Myeloproliferative Neoplasms and Multiple Myeloma
A Phase IIA, Open-label, Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BP1001 a Liposomal Grb2 Antisense Oligonucleotide in Combination with Venetoclax plus Decitabine in Patients with Acute Myeloid Leukemia AML Who Are Ineligible for Intensive Induction Therapy
A Phase I Study of Allogeneic Off-the-Shelf Multi-Tumor-Associated Antigen-Specific T Cell Products MT-401-OTS Administered to Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndromes RAPID
Study Type: Treatment
Phase: I
NCTID: NCT06552416
Principal Investigator:
Haitham Abdelhakim